ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026
ARL5B Drives Esophageal Squamous Cell Carcinoma Progression via ROCK1-SREBP1-Mediated Lipid Metabolic Reprogramming.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- LncRNA DLGAP1-AS2 promotes ESCC progression and indicates unfavorable prognosis via the miR-101-3p/EZH2 axis.Discover oncology · 2026Article
- Aneuploidy sensitizes cells to SREBP-pathway inhibition in squamous cell carcinoma.bioRxiv : the preprint server for biology · 2026Article
- FSCN1 Modulates Fatty Acid Metabolism and the Coordinated Activation of AKT/mTOR and p38 MAPK Pathways in Colorectal Cancer Cells.Oncology research · 2026Article
- ARL5B Drives Esophageal Squamous Cell Carcinoma Progression via ROCK1-SREBP1-Mediated Lipid Metabolic Reprogramming.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- The Role of COQ10B in Tumor Progression and Its Association with Immune Escape in Esophageal Squamous Cell Carcinoma: A Multi-Omics and Functional Analysis.International journal of general medicine · 2026Article
- RPL41 inhibits the proliferation and migration of retinoblastoma through the ARL5B-associated lysosomal trafficking.Frontiers in immunology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
Esophageal squamous cell carcinoma (ESCC) remains a highly aggressive malignancy with a 5 year survival rate below 30%, underscoring the urgent need for targeted therapeutic approaches. Here adenosine diphosphate (ADP)-ribosylation factor-like protein 5B (ARL5B) is identified as a key candidate oncogene that drives ESCC progression by modulating lipid metabolism via the ras homologous-associated coiled-coil containing protein kinase 1(ROCK1)-sterol regulatory element-binding protein 1 (SREBP1) signaling axis. Through the Cancer Genome Atlas (TCGA) pan-cancer analysis, ARL5B is initially identified as a promising candidate gene, correlating with advanced tumor, node, metastasis (TNM) stages and poor survival. Functional assays demonstrate that ARL5B knockdown significantly suppresses cell proliferation, invasion, and growth in vivo, while promoting apoptosis. Mechanistically, ARL5B facilitates the activation and nuclear translocation of SREBP1 through ROCK1, thereby enhancing lipogenic programming. Finally, pharmacological inhibition of either ROCK1 or SREBP1 abrogates the oncogenic effects induced by ARL5B overexpression, confirming the functional dependency on this pathway. These results establish ARL5B as a central regulator of lipid metabolism in ESCC and highlight its potential as a therapeutic target for precision oncology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.